Renal tubular protection effect of combining benazepril and spironolactone in adriamycin-induced nephritic rats

Abstract

Abstract: AIM: To investigate the renal tubular protection effect of combining benazepril and spironolactone in adriamycin-induced nephritic rats. METHODS: Male Sprague-Dawley(SD) rats were randomly separated to control group, model group, benazepril treatment group, spironolactone treatment group and combined treatment group. At the 6^th,12^th,18^th week, 24 hours urinary protein excretion were examined, meanwhile after 18th week the rats were executed, biochemical indicators and urinary retinene binding-protein(uRBP) were detected. Immunohistochemistry was performing to investigate renal pathological change and the expression of TGF-β₁. RESULTS: Contrast to model group, solo treatment groups and combined treatment group could efficiently lowered the blood pressure, proteinuria and increased serum-albumin(P<0.05), meanwhile, the combined group have most significant effect. Treatment groups could reduce the levels of uRBP excretion (P<0.01), the level of it in the combined group is lower than those of individual treamtment groups (P<0.01). The combined group could efficiently decrease the expression of TGF-β₁(P< 0.01). In the treatment groups, urinary RBP and TGF-β₁ was correlated significantly (r=0.735,r=0.845,r=0.585). CONCLUSION: In the adriamycin-induced nephropathic rats, combination of benazepril and spironolacton may decrease efficiently the content of protinuria, the level of uRBP and blood pressure, decrease the expression of TGF-β₁ in renal interstitial, arrest the progress of renal tubular injury.

Key words: Adriamycin-induced nephritic, rat, Benazepril, Spironolactone, Proteinuria, Urinary retinene binding-protein, Transforming growth factor-β₁

CLC Number:

R692.6

YANG Yan-lang^1,2, ZOU He-qun¹, ZHANG Dao-you², WANG Yu-wei², LI Fan-xia², GAO Chao-qing², XU Hai-hong², CHENG Xiao-mei². Renal tubular protection effect of combining benazepril and spironolactone in adriamycin-induced nephritic rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(4): 381-386.

References

[1] Rump LC.Secondary rise of albuminuria under ATl-receptor blockade-what is the potential role of aldosterone escape [J] ？ Nephrol Dial Transplant,2007,22(1):5-8.
[2] Hollenberg NK. Aldosterone in the development and progression of renal injury[J].Kidney Int, 2004,66(1):1-9.
[3] Lea J,Greene T,Hebert L,et a1.The relationship between magnitude of pmteinuria reduction and risk of end-stage renal disease:Results of the African American Study of Kidney Disease and hypertension[J].Arch Intern Med,2005,165(8):947-953.
[4] 杨沿浪,张道友,汪向明,等.苯那普利及己酮可可碱对阿霉素大鼠的肾脏保护作用 [J].中国临床药理学与治疗学,2009,14(7):22-26.
[5] Brown NJ, Nakamura S, Ma L, et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo[J]. Kidney Int, 2000,58(3) :1219 - 1227.
[6] O′Donnell MP. Renal tubulointerstitial fibrosis. New thoughts on its development and progression [J]. Postgrad Med, 2000,108(1):159-162.
[7] Juknevicius I, Segal Y, Kren S, et al. Effect of aldosterone on renal transforming growth factor2beta [ J ]. Am J Physiol Renal Physiol, 2004, 286 (6) : F1059 - F1062.
[8] Lahera V, Cachofeiro V, Balfagon G, et al. Aldosterone and its blockade: a cardiovascular and renal perspective [J]. Sci World J, 2006, 6:413-424.
[9] Feria I, Pichardo I, Juarez P, et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity[J]. Kidney Int, 2003,63(1):43-52.
[10] Fujisawa G, Okada K, Muto S, et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats [J]. Kidney Int, 2004, 66(4): 1493-1502.
[11] Epstein M. Aldosterone as a mediator of progressive renal dysfunction: evolving perspectives [J]. Intern Med, 2001, 40(7):573-583.
[12] Barbara LM. Serum and urinary biomarkers of acute kidney injury [J]. Blood Purif, 2010,29(4):357-365.
[13] Chrysostomou A,Pedagogos E,MacGregor L,et al.Double-bIind,placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin converting enzyme inhibitor therapy,with or without an angiotensinⅡreceptor blocker[J].CJASN,2006,1(2):256-262.
[14] Bianchi S,Bigazzi R,Campese VM.Antagonists of aldosterone and proteinuria in patients with CKD:an uncontrolled pilot study [J].AJKD,2005,46(1):45-51.
[15] Zoja C, Morigi M, Remuzzi G. Proteinuria and phenotypic change of proximal tubular cells [J]. JASN, 2003(Suppl 1),14: S36-41.
[16] Zoja C, Benigni A, Remuzzi G. Cellular responses to protein overload: key event in renal disease progression[J]. Curr Opin Nephrol Hypertens, 2004, 13(1): 31-37.